Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07470723 · ClinicalTrials.gov registry record · NA
The ORIGIN-FH Study
A NA study of Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia (HeFH), sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT07470723: Recruiting NA study of Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia (HeFH), sponsored by University of Wisconsin, Madison.
NCT07470723 is a NA study of Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia (HeFH) that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 70 participants, below the 216-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07470723, a NA study of Familial Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia (HeFH), is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to identify different types of Familial Hypercholesterolemia (FH) in infants and newborns. Participants will: * undergo a cheek swab for genetic testing (parents only) * have 5 blood samples collected Participants can expect to be in the trial for 2 years.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Screening for FH
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-02-14 |
| Est. Completion | 2029-02-14 |
| Phase | NA |
What NCT07470723 shows while recruiting
NCT07470723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 216-participant average among 7 other Familial Hypercholesterolemia trials with a reported enrollment target (68% lower).
The record links to 3 conditions, with Familial Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Screening for FH is the first listed.
NCT07470723 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT07470723 about?
NCT07470723 is a clinical study titled "The ORIGIN-FH Study". The goal of this clinical trial is to identify different types of Familial Hypercholesterolemia (FH) in infants and newborns. Participants will: * undergo a cheek swab for genetic testing (parents only) * have 5 blood samples collected Participants can expect to be in the trial for 2 years.
What is the current status of trial NCT07470723?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2026-02-14. Estimated completion is 2029-02-14.
What conditions does trial NCT07470723 study?
This clinical trial studies the following conditions: Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia (HeFH), Homozygous Familial Hypercholesterolemia (HoFH).
What interventions are being tested in trial NCT07470723?
The interventions under investigation include: Screening for FH (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07470723?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07470723 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Atlantic Lipid Lowering Treatment Optimization Program
RECRUITING · NA
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)
RECRUITING · Phase 2
-
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
ACTIVE NOT RECRUITING · Phase 3
-
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
COMPLETED
-
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI